Repligen Corporation (RGEN) support and resistance · P/E 143, rev $204.1M
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
This page maps Repligen Corporation (RGEN) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported RGEN revenue for 2026-06-30 was $204.1M. Net income was $5.0M. Revenue was up 5.1% from 2026-03-31 to 2026-06-30. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
RGEN currently screens at market cap $7.43B and trailing P/E 143.1. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new RGEN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the RGEN quote page for the session range and the stock page for the full model.
Not investment advice.